Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02131272 · ClinicalTrials.gov registry record · Phase 3
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 42
- Enrollment target
NCT02131272 is a Phase 3 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 42 participants.
The verdict
NCT02131272, a Phase 3 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 42 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination with the maximum tolerated dose of metformin and diet/exercise on glycaemic control in children and adolescents with type 2 diabetes insufficiently controlled on the maximum tolerated dose of metformin with or without other oral antidiabetic drug(s) with or without basal insulin.
Interventions
- DRUG Insulin NPH
- DRUG Insulin detemir
- BEHAVIORAL Diet/exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-06-11 |
| Est. Completion | 2016-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02131272
The ClinicalTrials.gov registry entry for NCT02131272 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Insulin NPH is the first listed.
NCT02131272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02131272 about?
NCT02131272 is a clinical study titled "A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin". This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination with the maximum tolerated dose of metformin and diet/exercise on glycaemic control in children and adolescents with type...
What is the current status of trial NCT02131272?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2014-06-11. Estimated completion is 2016-06-14.
What interventions are being tested in trial NCT02131272?
The interventions under investigation include: Insulin NPH (DRUG), Insulin detemir (DRUG), Diet/exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT02131272?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.